Literature DB >> 25773151

Vitamin D status and effect of interferon-β1a treatment on MRI activity and serum inflammation markers in relapsing-remitting multiple sclerosis.

Egil Røsjø1, Kjell-Morten Myhr2, Kristin I Løken-Amsrud3, Søren J Bakke4, Antonie G Beiske5, Kristian S Bjerve6, Harald Hovdal7, Finn Lilleås8, Rune Midgard9, Tom Pedersen10, Jūratė Šaltytė Benth11, Øivind Torkildsen12, Stig Wergeland13, Annika E Michelsen14, Pål Aukrust15, Thor Ueland14, Trygve Holmøy16.   

Abstract

To explore if vitamin D modulates interferon-β1a treatment effects in relapsing-remitting multiple sclerosis, we examined relationships between serum vitamin D and magnetic resonance imaging (MRI) activity and ten systemic inflammation markers in 88 patients, before and during treatment. Odds ratios for all MRI parameters were negatively associated with vitamin D levels before therapy, but converged to equally low values irrespective of vitamin D status during treatment. During therapy, similar alterations of MRI activity and inflammation markers were found across patients categorized by mean vitamin D values. This suggests that vitamin D status has no major influence on interferon-β1a treatment effects.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Interferon-β treatment; Relapsing-remitting multiple sclerosis; Vitamin D

Mesh:

Substances:

Year:  2015        PMID: 25773151     DOI: 10.1016/j.jneuroim.2015.02.001

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  6 in total

1.  Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis.

Authors:  Egil Røsjø; Linn H Steffensen; Lone Jørgensen; Jonas C Lindstrøm; Jūratė Šaltytė Benth; Annika E Michelsen; Pål Aukrust; Thor Ueland; Margitta T Kampman; Øivind Torkildsen; Trygve Holmøy
Journal:  J Neurol       Date:  2015-10-01       Impact factor: 4.849

2.  Vitamin D Status Does Not Affect Disability Progression of Patients with Multiple Sclerosis over Three Year Follow-Up.

Authors:  Anne-Hilde Muris; Joost Smolders; Linda Rolf; Lieke J J Klinkenberg; Noreen van der Linden; Steven Meex; Jan Damoiseaux; Raymond Hupperts
Journal:  PLoS One       Date:  2016-06-08       Impact factor: 3.240

3.  Association of vitamin D status and clinical and radiological outcomes in a treated MS population in Poland.

Authors:  Sławomir Wawrzyniak; Emilia Mikołajewska; Ewelina Kuczko-Piekarska; Anna Niezgodzińska-Maciejek; Aleksander Goch
Journal:  Brain Behav       Date:  2016-12-07       Impact factor: 2.708

4.  Natural Variation of Vitamin D and Neurofilament Light Chain in Relapsing-Remitting Multiple Sclerosis.

Authors:  Egil Røsjø; Jonas C Lindstrøm; Trygve Holmøy; Kjell-Morten Myhr; Kristin N Varhaug; Øivind Torkildsen
Journal:  Front Neurol       Date:  2020-04-30       Impact factor: 4.003

5.  Vitamin D and IFN-β Modulate the Inflammatory Gene Expression Program of Primary Human T Lymphocytes.

Authors:  Niccolò Bianchi; Stefan Emming; Chiara Zecca; Silvia Monticelli
Journal:  Front Immunol       Date:  2020-12-04       Impact factor: 7.561

Review 6.  Is there a window of opportunity for the therapeutic use of vitamin D in multiple sclerosis?

Authors:  Sofia Fernanda Goncalves Zorzella-Pezavento; Luiza Ayumi Nishiyama Mimura; Marina Bonifácio Denadai; William Danilo Fernandes de Souza; Thais Fernanda de Campos Fraga-Silva; Alexandrina Sartori
Journal:  Neural Regen Res       Date:  2022-09       Impact factor: 5.135

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.